Table 2 Identification and... | American Society of Hematology

Table 2

Identification and quantification of malignant clones by HTS

Patient no.*	Clonal TCR-β CDR3 AA sequence	% malignant T-cell clones
Patient no.*	Clonal TCR-β CDR3 AA sequence	Pretreatment	Week 8
1	CASSWGQDYGYTF	23.7	0.094
2	CASSEVREKLFF	5.8	3.9
3	CASSTGKYYGYTF	71.4	0
4	CASSLNAGGINQPQHF	42.8	17.5
5	CASSQAGKGGGPDTQYF	15.7	2.2
6	CASSQGTGPSSYEQYF	53.1	57.4
7	Clone not identified
8	CASSPSDITRDQPQHF	3.6	0
9	CASSGAYTGELFF	43.5	12.8
10	CAISRTGGTLRSGANVLTF	37.5	30.5
11	CASSQDMFGMERLNSPLHF	19.2	0

Patient no.*	Clonal TCR-β CDR3 AA sequence	% malignant T-cell clones
Patient no.*	Clonal TCR-β CDR3 AA sequence	Pretreatment	Week 8
1	CASSWGQDYGYTF	23.7	0.094
2	CASSEVREKLFF	5.8	3.9
3	CASSTGKYYGYTF	71.4	0
4	CASSLNAGGINQPQHF	42.8	17.5
5	CASSQAGKGGGPDTQYF	15.7	2.2
6	CASSQGTGPSSYEQYF	53.1	57.4
7	Clone not identified
8	CASSPSDITRDQPQHF	3.6	0
9	CASSGAYTGELFF	43.5	12.8
10	CAISRTGGTLRSGANVLTF	37.5	30.5
11	CASSQDMFGMERLNSPLHF	19.2	0

Patient 12 was not biopsied for HTS analyses.